June is Cancer Immunotherapy Awareness Month, an initiative to increase the public’s awareness of the revolutionary new treatment approach. Cancer immunotherapy utilises the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer. BioMed Central and the Society for Immunotherapy of Cancer (SITC) are therefore pleased to announce the timely launch of the Journal for ImmunoTherapy of Cancer (JITC), an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

As the official journal of SITC, JITC will be the cancer immunotherapy community’s prime forum to discuss the critical issues in tumor immunology and cancer immunotherapy research, with an audience of the most influential names in the field. The journal is overseen by Editor-in-Chief Pedro Romero, as well as an Editorial Board of outstanding leaders in both basic and clinical tumor immunology and cancer immunotherapy fields. SITC members will also receive waived article processing charges for manuscripts published in the journal during 2013.

The journal’s inaugural articles include an Editorial by the Editor-in-Chief and SITC, a Review article on the regulation of cancer immunotherapeutic products and the FDA’s role in their development and clinical evaluation, and the society’s Annual Meeting report. You can read all of the published articles, and find out more about JITC, via the journal’s website, where you can also submit a manuscript.